Survival, Prognostic Factors, and Rates of Leukemic Transformation in a Multicenter Study of 303 Untreated Patients with MDS and Del(5q).

Autor: Germing, Ulrich, Lauseker, Michael, Hildebrandt, Barbara, Symeonidis, Argiris, Cermak, Jaroslav, Pfeilstöcker, Michael, Nösslinger, Thomas, Sekeres, Mikkael A., Maciejewski, Jaroslaw P., Haase, Detlef, Schanz, Julie, Seymour, Jf, Weide, Rudolf, Lübbert, Michael, Platzbecker, Uwe, Valent, Peter, Götze, Katharina, Stauder, Reinhard, Blum, Sabine, Kreuzer, Karl Anton, Schlenk, Richard F., Aul, Carlo, Kündgen, Andrea, Hasford, Joerg, Giagounidis, Aristoteles
Zdroj: Blood; November 2009, Vol. 114 Issue: 22 p945-945, 1p
Abstrakt: Germing: Novartis, Celgene: Honoraria, Research Funding. Lauseker:Celgene: Research Funding. Hildebrandt:Celgene: Research Funding. Symeonidis:Celgene: Research Funding. Cermak:Celgene: Research Funding. Pfeilstöcker:Celgene: Research Funding. Nösslinger:Celgene: Research Funding. Sekeres:Celgene: Research Funding. Maciejewski:Celgene: Research Funding. Haase:Celgene: Research Funding. Schanz:Celgene: Research Funding. Seymour:Celgene: Research Funding. Weide:Celgene: Research Funding. Lübbert:Celgene: Research Funding. Platzbecker:Celgene: Research Funding. Valent:Celgene: Research Funding. Götze:Celgene: Research Funding. Stauder:Celgene: Research Funding. Blum:Celgene: Research Funding. Kreuzer:Celgene: Research Funding. Schlenk:Celgene: Research Funding. Aul:Celgene: Research Funding. Kündgen:Celgene: Research Funding. Hasford:Celgene: Research Funding. Giagounidis:Celgene: Research Funding.
Databáze: Supplemental Index